LifeMD Launches $299 Introductory Wegovy® Bundle for Self-Pay Patients in Collaboration with Novo Nordisk

What You Should Know: 

– LifeMD, Inc., a provider of virtual primary care services announced a limited-time $299 introductory bundle for new self-pay patients prescribed Wegovy® (semaglutide). 

– The comprehensive package includes both the GLP-1 medication and access to LifeMD’s virtual weight management program. The initiative is part of LifeMD’s collaboration with Novo Nordisk, announced last month, and leverages a recently completed integration with NovoCare® Pharmacy to offer Wegovy® at a discounted price of $199 for eligible patients, with an additional $100 covering LifeMD’s clinical care, onboarding, and ongoing support.

– The bundled offer aims to improve affordability and access for the growing number of self-pay patients seeking FDA-approved options for medical weight loss, particularly as an alternative to compounded therapies.

Affordable On-Ramp to FDA-Approved GLP-1 Therapy

The $299 introductory bundle is available to eligible new patients who are prescribed Wegovy® on or before June 30, 2025. Following the first month, the program will cost $599 per month, with no long-term commitment required. The offer is designed for patients who are uninsured or whose insurance does not cover prescription weight-loss medications.

“Our collaboration with Novo Nordisk reflects LifeMD’s commitment to improving affordability, convenience, and access for patients seeking medically guided weight loss,” said Justin Schreiber, Chairman and CEO of LifeMD. “This bundled solution provides a seamless, affordable on-ramp to FDA-approved GLP-1 therapy—replacing the fragmented and often inconsistent experience many patients have faced with compounded alternatives. We look forward to expanding this collaboration to reach more patients and drive better outcomes at scale.”

Strengthening Access to Authentic Wegovy® Through Virtual Care

Wegovy® is noted as the first GLP-1 therapy approved in the United States for both chronic weight management and cardiovascular risk reduction in adults with obesity. Through this offering, all doses of Wegovy® are available in an injector pen, by prescription, to eligible LifeMD patients. The collaboration with Novo Nordisk strengthens LifeMD’s capacity to deliver branded GLP-1 medications through a fully integrated virtual care experience.

LifeMD’s Integrated Virtual Weight Management Program

LifeMD’s weight management program provides personalized, clinically guided care for patients across the U.S.. The company leverages its vertically integrated platform, which includes a 50-state medical group and national diagnostic lab partnerships, to offer a seamless experience from initial virtual consultation through prescription fulfillment and ongoing coaching and support. This end-to-end model ensures continuity of care at every stage of a patient’s weight loss journey.To learn more about LifeMD’s $299 introductory bundled offering with Wegovy®, interested individuals can visit https://lifemd.com/wegovy/.